Irinotecan
Poor Performance Status
University of California, DavisSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Poor Performance Status cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Famitinib Guangzhou Institute of Respiratory Disease | Phase 1 | CC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →